Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca's Brilinta Beats Aspirin in Trial for Reducing Stroke Chances

By Mark Prvulovic - Jan 27, 2020 at 3:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Strong late-stage clinical trial results are helping bolster this blood thinner's appeal.

AstraZeneca (AZN 0.30%) announced that its blood thinner drug Brilinta met its primary endpoint in a late-stage trial. Patients that had taken a combined treatment of Brilinta and aspirin saw a significant reduction in the chance of stroke or death in comparison to patients that just took aspirin alone.

The phase 3 Thales study, which featured over 11,000 patients, tested whether the two drugs taken together could reduce the chance of stroke in patients that already had a previous stroke. Patients had been given a 180-milligram initial dose via injection on the first day, followed by smaller doses through the next couple of days. The main adverse event from patients taking Brilinta was an increased bleeding rate in the arm that took the treatment, which was expected.

Picture of a person with symptoms of a brain stroke.

Image source: Getty Images.

"While an expected increase in bleeding was observed, the findings from THALES showed that Brilinta, in combination with aspirin, reduced the risk of potentially devastating events," said Dr. Clay Johnson, lead investigator of the trial. AstraZeneca plans to present the full data in an upcoming medical meeting, although it wasn't specified which one.

Brilinta's History

Brilinta was first approved by the Food and Drug Administration (FDA) in 2011 to reduce the chance of heart attacks in patients with acute coronary syndrome. Since then, the drug has received expanded approval for long-term use in patients at high risk of heart attacks.

The phase 3 Thales trial results are a complete reversal of an earlier study conducted in 2016, which showed Brilinta was no better at reducing strokes than aspirin alone. It's a welcome turnaround for the pharmaceutical giant, which has high hopes for Brilinta.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.41 (0.30%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.